Skip to main content
Premium Trial:

Request an Annual Quote

Toxic Reports Buys PathoGenetix's Pathogen ID Technology

NEW YORK (GenomeWeb) – Analytical testing firm Toxic Reports has acquired the assets of pathogen identification firm PathoGenetix for an undisclosed amount.

The Watertown, Mass.-based firm now owns all the intellectual property and proprietary designs of the Resolution Microbial Genotyping System that PathoGenetix had been developing. Toxic Reports said it is proceeding with the design and manufacture of the full commercial version of the system and plans to sell it directly to customers starting next month. 

Initial applications for the platform will be in bacterial pathogen identification in the food safety and public health and epidemiology spaces, it said. 

PathoGenetix, which was headquartered in Woburn, Mass., filed for Chapter 7 bankruptcy during the summer. The company was founded in 1997 as US Genomics. 

The Resolution System is based on a genotyping technology called Genome Sequencing Scanning for detecting pathogens in environmental samples. Toxic Reports noted that MRIGlobal, an independent contract research firm, purchased an early commercial version of the Resolution System last April and is using it in a government-funded project.

Toxic Reports said that the purchase of PathoGenetix's assets expands its product and services from the analyses of simple organic molecules to include the characterization of bacteria in environmental and food samples. 

The Scan

Support for Moderna Booster

An FDA advisory committee supports authorizing a booster for Moderna's SARS-CoV-2 vaccine, CNN reports.

Testing at UK Lab Suspended

SARS-CoV-2 testing at a UK lab has been suspended following a number of false negative results.

J&J CSO to Step Down

The Wall Street Journal reports that Paul Stoffels will be stepping down as chief scientific officer at Johnson & Johnson by the end of the year.

Science Papers Present Proteo-Genomic Map of Human Health, Brain Tumor Target, Tool to Infer CNVs

In Science this week: gene-protein-disease map, epigenomic and transcriptomic approach highlights potential therapeutic target for gliomas, and more